Targeting Soluble Amyloid Oligomers in Alzheimer’s Disease: A Hypothetical Model Study Comparing Intrathecal Pseudodelivery of mAbs Against Intravenous Administration
Background/Objective: Neurotoxic soluble amyloid-β (Aβ) oligomers are key drivers of Alzheimer’s pathology, with evidence suggesting that early targeting of these soluble forms may slow disease progression. Traditional intravenous (IV) monoclonal antibodies (mAbs) face challenges, including limited...
Saved in:
Main Author: | Manuel Menendez-Gonzalez |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Diseases |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-9721/13/1/17 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CD22 modulation alleviates amyloid β-induced neuroinflammation
by: Yu Dong Mai, et al.
Published: (2025-02-01) -
Degradation of amyloid β-peptides catalyzed by nattokinase in vivo and in vitro
by: Aixin Ni, et al.
Published: (2023-09-01) -
Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
by: Jimin Kim, et al.
Published: (2025-01-01) -
Structural Analysis of Amylin and Amyloid β Peptide Signaling in Alzheimer’s Disease
by: Longsheng Xie, et al.
Published: (2025-01-01) -
Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer’s disease: an overview of pre-clinical studies focused on β-amyloid peptide
by: Kumju Youn, et al.
Published: (2022-05-01)